Though warranted in HNSCC in general, careful patient selection or retrospective analysis may be necessary, as HPV+, mTOR activated, or therapy resistant recurrent/metastatic disease may be of greatest benefit. The gene discussed is MTOR; the disease is metastatic neoplasm.